Baidu
map

心血管指南

订阅

MedSci主页 / 所有栏目 / 心血管指南

2021 ESC共识文件：心力衰竭调整药物治疗的患者特征

2021-06-30 欧洲心脏病学会 Eur J Heart Fail.2021 Jun;23(6):872-881.

心力衰竭

心力衰竭患者治疗的执行情况较差，多数患者没有按照目标记录服药，这对于发病率和死亡率均有影响。此外，与低血压、心率、盛宁受损或高钾血症相关的耐受性问题也是原因之一。本文主要针对心衰患者调整药物治疗提供指

中文标题：

2021 ESC共识文件：心力衰竭调整药物治疗的患者特征

英文标题：

Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology

发布机构：

欧洲心脏病学会

发布日期：

2021-06-30

简要介绍：

心力衰竭患者治疗的执行情况较差，多数患者没有按照目标记录服药，这对于发病率和死亡率均有影响。此外，与低血压、心率、盛宁受损或高钾血症相关的耐受性问题也是原因之一。本文主要针对心衰患者调整药物治疗提供指导。

 

相关资料下载：
[AttachmentFileName(sort=1, fileName=2021 ESC共识文件：心力衰竭调整药物治疗的患者特征.pdf)] GetToolGuiderByIdResponse(projectId=1, id=390a51c0021a1543, title=2021 ESC共识文件：心力衰竭调整药物治疗的患者特征, enTitle=Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology, guiderFrom=Eur J Heart Fail.2021 Jun;23(6):872-881., authorId=0, author=, summary=心力衰竭患者治疗的执行情况较差，多数患者没有按照目标记录服药，这对于发病率和死亡率均有影响。此外，与低血压、心率、盛宁受损或高钾血症相关的耐受性问题也是原因之一。本文主要针对心衰患者调整药物治疗提供指, cover=https://img.medsci.cn/2021731/1627738480611_2020535.jpg, journalId=0, articlesId=null, associationId=62, associationName=欧洲心脏病学会, associationIntro=是目前在欧洲居于首要地位的心脏病学会，会员超过70000人、提供更新指南、调查数据、组织学术会议，ESC年会是心血管领域最大的会议。下设5个分会（超声心动图学会、心律学会、心衰学会、预防与康复学会及介入学会）。提供指南较全面，按年份排列。现提供有手机板本。, copyright=0, guiderPublishedTime=Wed Jun 30 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>心力衰竭患者治疗的执行情况较差，多数患者没有按照目标记录服药，这对于发病率和死亡率均有影响。此外，与低血压、心率、盛宁受损或高钾血症相关的耐受性问题也是原因之一。本文主要针对心衰患者调整药物治疗提供指导。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=335, tagName=心力衰竭)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=335, guiderKeyword=心力衰竭, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3180, appHits=209, showAppHits=0, pcHits=495, showPcHits=2968, likes=1, shares=4, comments=6, approvalStatus=1, publishedTime=Sat Jul 31 22:52:04 CST 2021, publishedTimeString=2021-06-30, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Sat Jul 31 21:34:46 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 12:49:41 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 ESC共识文件：心力衰竭调整药物治疗的患者特征.pdf)])
2021 ESC共识文件：心力衰竭调整药物治疗的患者特征.pdf
下载请点击：
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1072744, encodeId=089110e274438, content=还是得学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef2c1960942, createdName=1e1366a1m07(暂无匿称), createdTime=Mon Nov 22 10:07:44 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1072743, encodeId=a40b10e2743f8, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef2c1960942, createdName=1e1366a1m07(暂无匿称), createdTime=Mon Nov 22 10:07:22 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055942, encodeId=5b3010559423e, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Wed Sep 29 08:57:01 CST 2021, time=2021-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007392, encodeId=039a100e3921c, content=厉害, beContent=null, objectType=guider, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73f02135654, createdName=1571fdc029m, createdTime=Thu Aug 12 20:44:39 CST 2021, time=2021-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007345, encodeId=5aa6100e3457f, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16dd5569788, createdName=ms9000000533661856, createdTime=Thu Aug 12 17:56:35 CST 2021, time=2021-08-12, status=1, ipAttribution=)]
    2021-11-22 1e1366a1m07(暂无匿称)

    还是得学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1072744, encodeId=089110e274438, content=还是得学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef2c1960942, createdName=1e1366a1m07(暂无匿称), createdTime=Mon Nov 22 10:07:44 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1072743, encodeId=a40b10e2743f8, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef2c1960942, createdName=1e1366a1m07(暂无匿称), createdTime=Mon Nov 22 10:07:22 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055942, encodeId=5b3010559423e, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Wed Sep 29 08:57:01 CST 2021, time=2021-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007392, encodeId=039a100e3921c, content=厉害, beContent=null, objectType=guider, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73f02135654, createdName=1571fdc029m, createdTime=Thu Aug 12 20:44:39 CST 2021, time=2021-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007345, encodeId=5aa6100e3457f, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16dd5569788, createdName=ms9000000533661856, createdTime=Thu Aug 12 17:56:35 CST 2021, time=2021-08-12, status=1, ipAttribution=)]
    2021-11-22 1e1366a1m07(暂无匿称)

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1072744, encodeId=089110e274438, content=还是得学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef2c1960942, createdName=1e1366a1m07(暂无匿称), createdTime=Mon Nov 22 10:07:44 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1072743, encodeId=a40b10e2743f8, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef2c1960942, createdName=1e1366a1m07(暂无匿称), createdTime=Mon Nov 22 10:07:22 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055942, encodeId=5b3010559423e, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Wed Sep 29 08:57:01 CST 2021, time=2021-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007392, encodeId=039a100e3921c, content=厉害, beContent=null, objectType=guider, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73f02135654, createdName=1571fdc029m, createdTime=Thu Aug 12 20:44:39 CST 2021, time=2021-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007345, encodeId=5aa6100e3457f, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16dd5569788, createdName=ms9000000533661856, createdTime=Thu Aug 12 17:56:35 CST 2021, time=2021-08-12, status=1, ipAttribution=)]
    2021-09-29 H8888888

    感谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1072744, encodeId=089110e274438, content=还是得学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef2c1960942, createdName=1e1366a1m07(暂无匿称), createdTime=Mon Nov 22 10:07:44 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1072743, encodeId=a40b10e2743f8, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef2c1960942, createdName=1e1366a1m07(暂无匿称), createdTime=Mon Nov 22 10:07:22 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055942, encodeId=5b3010559423e, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Wed Sep 29 08:57:01 CST 2021, time=2021-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007392, encodeId=039a100e3921c, content=厉害, beContent=null, objectType=guider, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73f02135654, createdName=1571fdc029m, createdTime=Thu Aug 12 20:44:39 CST 2021, time=2021-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007345, encodeId=5aa6100e3457f, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16dd5569788, createdName=ms9000000533661856, createdTime=Thu Aug 12 17:56:35 CST 2021, time=2021-08-12, status=1, ipAttribution=)]
    2021-08-12 1571fdc029m

    厉害

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1072744, encodeId=089110e274438, content=还是得学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef2c1960942, createdName=1e1366a1m07(暂无匿称), createdTime=Mon Nov 22 10:07:44 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1072743, encodeId=a40b10e2743f8, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef2c1960942, createdName=1e1366a1m07(暂无匿称), createdTime=Mon Nov 22 10:07:22 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055942, encodeId=5b3010559423e, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Wed Sep 29 08:57:01 CST 2021, time=2021-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007392, encodeId=039a100e3921c, content=厉害, beContent=null, objectType=guider, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73f02135654, createdName=1571fdc029m, createdTime=Thu Aug 12 20:44:39 CST 2021, time=2021-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007345, encodeId=5aa6100e3457f, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16dd5569788, createdName=ms9000000533661856, createdTime=Thu Aug 12 17:56:35 CST 2021, time=2021-08-12, status=1, ipAttribution=)]
    2021-08-12 ms9000000533661856

    谢谢分享

    0

相关指南

钙增敏剂在心力衰竭中的临床应用专家建议

中国医师协会心血管内科医师分会(CCCP,Chinese College of Cardiovascular Physicians) · 2021-05-27

2021 CCS/CHFS心衰指南更新：定义新的射血分数降低心力衰竭药理学标准

加拿大心血管学会(CCS,Canadian Cardiovascular Society) · 2021-04-03

2021 HFA/EACVI/EHRA/EAPCI立场声明：心力衰竭患者继发二尖瓣反流的管理

欧洲心力衰竭协会(HFA,Heart Failure Association) · 2021-03-18

房间隔分流器治疗射血分数保留心力衰竭：中国专家认识和建议

中国医师协会心血管内科医师分会(CCCP,Chinese College of Cardiovascular Physicians) · 2020-12-30

2021 法国专家共识：高龄患者心力衰竭的管理

法国老年学及老年病学学会(FSGG,French Society of Gerontology and Geriatrics) · 2021-01-14

2020心肌梗死后心力衰竭防治专家共识

中国医师协会心血管内科医师分会(CCCP,Chinese College of Cardiovascular Physicians) · 2020-12-30

拓展阅读

2010 中华医学会 急性心力衰竭诊断和治疗指南

中华医学会心血管病学分会(Chinese Society of Cardiology) · 2010-01-01

心脏再同步治疗慢性心力衰竭的建议（2009年修订版）

中华医学会心电生理和起搏分会 · 2010-02-25

加拿大心衰诊疗指南（2010更新）：少数民族人口，心脏衰竭和怀孕，疾病管理，和质量改进/保证方案心力衰竭

加拿大心血管学会(CCS,Canadian Cardiovascular Society) · 2010-04-01

2010HFSA 心力衰竭治疗指南

美国心衰学会(HFSA,HEART FAILURE SOCIETY OF AMERICA) · 2010-07-01

2011AHA/ACC 急性心力衰竭综合征：急诊科表现、治疗、处置的现状及预期目的--来自美国心脏病协会科学声明

美国心脏协会(AHA,American Heart Association) · 2011-04-14

2012AHA 科学声明：心力衰竭诊疗进展科学决策

美国心脏协会(AHA,American Heart Association) · 2012-03-05

Baidu
map
Baidu
map
Baidu
map